Respiratory and cardiovascular effects of combined therapy with indacaterol and glycopyrronium bromide in chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2015-25-6-747-752
Abstract
The aim of this article was to investigate respiratory and cardiovascular effects of combined therapy with indacaterol and glycopyrronium bromide in patients with severe chronic obstructive pulmonary disease.
Methods. Two clinical cases are reported in the article. Both patients were treatment with longacting beta2agonist indacaterol for 3 months followed by 3month treatment with combined therapy with indacaterol and glycopyrro nium bromide. We assessed arterial stiffness, pulse wave velocity rate, the heart rhythm variability, used spirometry and echocardiography, CAT and MMRC scales.
Results. Combined inhalation therapy resulted in significant increase in FEV1 and FVC, reduction in dyspnea, improvement in arterial oxygen saturation. Arterial stiffness was not changed, but the heart rhythm autonomic regulation improved in both patients. A tendency to increase in the left heart ejection fraction was also found.
Conclusion. Our data are consistent with results of other clinical trials of indacaterol and glycopyrronium bromide in patients with chronic obstructive pulmonary disease.
About the Authors
N. Sh. Zagidullin
Bashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
MD, Assistant Professor, Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397
R. Kh. Zulkarneev
Bashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
PhD student at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397
Yu. F. Safina
Bashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
MD, Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397
Yu. G. Aznabaeva
Bashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
PhD, Associate Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 2465397
Sh. Z. Zagidullin
Bashkir State Medical University: 3, Lenina str., Ufa, 450000, Bashkortostan Republic, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Health care Ministry of Russia; tel.: (347) 2465397
References
1. Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.com
2. Beeh K.M., Beier J. Indacaterol: a new once daily longacting beta2adrenoceptor agonist. Core Evidence. 2009; 4: 37–41.
3. Feldman G., Siler T, Prasad N. et al. Efficacy and safety of indacaterol 150 microg oncedaily in COPD: a doubleblind, randomised, 12week study. BMC Pulm. Med. 2010; 10: 11.
4. Chapman K.R., Rennard S.I., Dogra A. et al. Longterm safety and efficacy of indacaterol, a longacting β2agonist, in subjects with COPD: a randomized, placebocontrolled study. Chest. 2011; 140 (1): 68–75.
5. Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily longacting inhaled β2agonist indacaterol versus twicedaily formoterol in COPD. Thorax. 2010; 65: 473–479.
6. Buhl R., Banerji D. Profile of glycopyrronium for once daily treatment of moderatetosevere COPD. Int. J. COPD. 2012; 7: 729–741.
7. Ulrik C.S. Oncedaily glycopyrronium bromide, a longacting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. COPD. 2012; 7: 673–678.
8. Barnes P.J. Anticholinergic Therapy in Obstructive Airway Disease. Ed. by N.Gross. London; 1993: 88–104.
9. Brown J.H., Taylor P. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. Ed. by J.G. Hardman et al. New York; 1996: 141.
10. Lange P., Mogelvang R., Marott J.L. et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010; 7: 5–10.
11. Konecny T., Park J.Y., Somers K.R. et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am. J. Cardiol. 2014; 15: 114 (2): 272–277.
12. Zulkarneev R., Zagidullin N., Abdrahmanova G. et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals. 2012; 5 (4): 398–404.
13. Hanrahan J.P., Grogan D.R., Baumgartner R.A. et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled longacting beta2agonists arfor moterol and salmeterol. Medicine (Baltimore). 2008; 87 (6): 319–328.
14. Karvandi M., Piranfar M.A., Ghaffaripour M. et al. An alternative method for perioperative estimation of pulmonary artery systolic pressure by echocardiography. Shiraz E*Med. J. 2007; 8: 4:174–182.
15. Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 2006; 16: 63–70.
16. Schneider C., Bothner U., Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur. J. Epidemiol. 2010; 25: 253–260.
17. Roque A.L., Valenti V.E., Massetti T. et al. Chronic obstructive pulmonary disease and heart rate variability: a literature update. Int. Arch. Med. 2014; 3 (7): 43.
18. Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041.
19. Worth H., Fan Chung K., Felser K. et al. Cardio and cere brovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir. Med. 2011; 105: 571–579.
20. Bateman E., Ferguson G.T., Barnes N. et al. Dual bron chodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.
21. Mahler D., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patientreported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.
22. Wedzicha J., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopy rronium and tiotropium (SPARK): a randomised, double blind, parallelgroup study. The Lancet. Lancet Respir. Med. 2013; 1 (3): 199–209.
23. Zhong N., Wang C., Zhou W. LANTERN: a randomized study of QVa149 versus salmeterol / fluticasone combination in patients with COPD. Int. J. COPD. 2015; 10: 1015–1026.
Review
For citations:
Zagidullin N.Sh., Zulkarneev R.Kh., Safina Yu.F., Aznabaeva Yu.G., Zagidullin Sh.Z. Respiratory and cardiovascular effects of combined therapy with indacaterol and glycopyrronium bromide in chronic obstructive pulmonary disease. PULMONOLOGIYA. 2015;25(6):747-752. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-6-747-752
Views:
662
Email this article 